Funding round completed for Belfast-based developer of novel oncology biologics

An investment of £137.4k has been secured by Finn Therapeutics Ltd, valuing the business at an estimated £241.4k post-money. The company develops first-in-class therapeutic antibodies that provide anti-angiogenic and immunomodulatory treatment for advanced renal cell carcinoma and other solid tumours.

The biotechnology firm was incorporated in 2020 to address unmet cancer needs. It operates as a lean, asset-centric entity, leveraging years of experience in preclinical and clinical CRO drug development to advance its drug discovery pipeline. The startup lists its website as finn-therapeutics.com.

Latest accounts for the year ended 31 December 2025 record a headcount of two employees. This capital injection follows a share allotment that took place in August (filed in September).